Compare iShares MSCI Taiwan ETF (EWT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.9 (market cap $12.87B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.31B). The key difference: iShares MSCI Taiwan ETF is far larger — about 5.6× Recursion Pharmaceuticals Inc's market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWT | RXRX | |
|---|---|---|
Market Cap | $12.87B | $2.31B |
Volume | 4,043,927 | 40,478,768 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $6.79 |
52-Week Low | $60.03 | $2.84 |
Typical Hold Time | 52 Days | 22 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT trades at $116.24, down 1.16% today, with a bullish technical outlook supported by moving averages. The ETF remains heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights continued US-Taiwan economic cooperation and institutional buying interest.
The outlook remains positive given Taiwan's strategic position in AI supply chains, though geopolitical tensions pose significant risks. Valuation appears reasonable for tech exposure, but investors must weigh semiconductor cyclicality against long-term growth potential in artificial intelligence infrastructure.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
